Breaks Categories: News

ThursdayJan 20, 2022 9:56 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Unveils Newly Designed Corporate Website

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the launch of its newly designed website. According to the update, the new site conveys the company’s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. “We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics,” said Anthony Durkacz, interim CEO of FSD Pharma. “With some of the greatest minds in…

Continue Reading

WednesdayJan 19, 2022 9:32 am

PsychedelicNewsBreaks – Microdose Psychedelic Insights’ Upcoming Conference to Showcase Top Companies, Newest Opportunities Within Psychedelics Sector

Microdose Psychedelic Insights, the leading guide to the business of psychedelics, will be hosting the upcoming Psychedelic Capital: January 2022 Conference in an entirely virtual format on Jan. 27, 2022, starting at 1:30 p.m. EST. The event will shine the spotlight on some of the top companies, latest IPOs, newest opportunities and deepest industry insights within the psychedelics sector. As part of a bimonthly investor conference series that dives deep into psychedelic medicine investment, the event will introduce attendees to a curated group of CEOs, capital advisors and investment luminaries from around the world. The event will start with a…

Continue Reading

TuesdayJan 18, 2022 2:40 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Releases Results of Harris Survey on Psychedelics as an Alternative Treatment

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that nearly two-thirds (65%) of Americans who suffer from anxiety, depression and PTSD believe that psychedelic medicine, including ketamine, psilocybin and MDMA, should be available to patients with treatment-resistant anxiety, depression or PTSD. The online survey included 953 adults living in the United States who suffer from anxiety, depression or PTSD. Of those surveyed, 63% of those who have used prescription medications for treatment response that, while the medication helped, they still experienced residual feelings of anxiety, depression or…

Continue Reading

TuesdayJan 18, 2022 2:11 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), The Newly Partner to Set the Gold Standard for Psychedelic-Assisted Therapies

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced its entry into a letter of intent (“LOI”) with The Newly Institute Inc. (“The Newly”), a Calgary, Alberta based company opening private inter-disciplinary mental health clinics across Canada. The companies will collaborate on expanding psychedelic-assisted psychotherapy to patients and, together, create the package of resources needed for patients and practitioners to successfully gain acceptance into Health Canada's Special Access Program (“SAP”). The Newly is the first partner under Mydecine's recently announced Special Access Support…

Continue Reading

ThursdayJan 13, 2022 12:38 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Eyes Strong Outlook for Growth and Profitability

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today issued a corporate update. Among the highlights, Delic reported that it has 12 strategically located and operational clinics with 15 more opening in the next 18 months. “There are 51.5 million Americans who have experienced a mental health condition and the ongoing pandemic has only exacerbated the crisis,” said Matt Stang, co-founder and CEO of Delic. “We are seeing a strong demand for alternatives to current treatments with lasting outcomes and less side effects. At Delic, we have built the…

Continue Reading

ThursdayJan 13, 2022 11:28 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Launches Canadian Program to Support Psychedelic-Assisted Psychotherapy

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has unveiled its Special Access Support and Supply Program (“SASSP”). The program provides products, services and support to hospitals, clinics and physicians in Canada who utilize psychedelic-assisted psychotherapy treatment. Health Canada recently added psilocybin and MDMA to its approved list of substances in its Special Access Program (“SAP”), creating an opportunity for MYCOF to provide critical resources in helping thousands of healthcare professionals and clinics offer these treatments to those in need. The Health Canada announcement allows…

Continue Reading

TuesdayJan 11, 2022 1:27 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Featured in Latest Episode of Bell2Bell Podcast

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health disorders and addiction, was featured in the Bell2Bell Podcast, a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Mydecine’s co-founder, chairman and CEO Josh Bartch joined the latest episode to discuss the company’s business model, highlighting its phased approach to developing improved treatment options for a variety of underserved indications. “Mydecine Innovations Group… is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a…

Continue Reading

TuesdayJan 11, 2022 12:35 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Opens Salt Lake City Clinic

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that its subsidiary, Ketamine Wellness Centers (“KWC”), has officially expanded operations into Utah with the opening of its Salt Lake City location. Acquired by Delic in September 2021, KWC currently operates 11 ketamine infusion treatment clinics across nine states, delivering more than 61,000 treatments to date. “Utah currently experiences one of the highest rates of mental health concerns in the country with lower access to care, and KWC aims to serve this new community of patients struggling with treatment-resistant…

Continue Reading

TuesdayJan 11, 2022 12:28 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures IRB Approval for Feasibility Study Using Kernel’s Quantitative Neuroimaging Technology

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that an Institutional Review Board (“IRB”) has approved a company-sponsored feasibility study. The study will use Kernel’s quantitative neuroimaging technology, Kernel Flow, to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. As part of its sponsorship of the feasibility study, Cybin will retain an exclusive interest in any innovations discovered or developed through its independent analysis of the findings. “By leveraging the Kernel Flow technology, we may have the ability to measure longitudinal brain activity before, during and after a psychedelic experience, and…

Continue Reading

MondayJan 10, 2022 11:11 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Present at HC Wainwright Bioconnect Virtual Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced details regarding its participation at today's HC Wainwright Bioconnect Virtual Conference. The company’s co-founder and CEO Matt Stang will present on Delic’s expansion strategy and industry outlook heading into 2022 and offer one-on-one meetings with investors. Interested parties should visit https://ibn.fm/eTcfl to register for the event, access Delic's presentation and sign up for a one-on-one meeting. To view the full press release, visit https://ibn.fm/oXYCz Delic Holdings Corp. Delic is a leader in new medicines and treatments for a modern…

Continue Reading